Emergent BioSolutions (EBS) Receivables - Net (2010 - 2026)

Emergent BioSolutions' Receivables - Net history runs 17 years deep, the most recent figure standing at $121.6 million for Q1 2026.

• On a quarterly basis, Receivables - Net fell 40.3% year-over-year to $121.6 million in Q1 2026; TTM through Mar 2026 was $121.6 million, a 40.3% decrease from a year earlier, with the FY2025 full-year figure at $84.2 million, down 45.5% from the prior year.
• Receivables - Net rose to $121.6 million in Q1 2026 per EBS's latest filing, from $66.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $290.1 million in Q2 2023 and bottomed at $66.8 million in Q4 2025.
• The 5-year median for Receivables - Net is $175.0 million (2022), against an average of $166.4 million.
• Across the five-year window, Receivables - Net tumbled 63.18% in 2022 and jumped 85.98% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $102.7 million in 2022, then surged by 85.98% to $191.0 million in 2023, then dropped by 19.11% to $154.5 million in 2024, then plunged by 56.76% to $66.8 million in 2025, then surged by 82.04% to $121.6 million in 2026.
• Per Business Quant, the three latest EBS Receivables - Net figures stand at $121.6 million (Q1 2026), $66.8 million (Q4 2025), and $149.5 million (Q3 2025).